Last Updated: November 9, 2026

ORPHENADRINE CITRATE Drug Patent Profile

Name: ORPHENADRINE CITRATE Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

When do Orphenadrine Citrate patents expire, and what generic alternatives are available?

Orphenadrine Citrate is a drug marketed by Hikma, Rising, Sagent Pharms, Watson Labs, Ascot, Lupin, Sandoz, Stevens J, and Unichem. and is included in fifteen NDAs.

The generic ingredient in ORPHENADRINE CITRATE is aspirin; caffeine; orphenadrine citrate. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aspirin; caffeine; orphenadrine citrate profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ORPHENADRINE CITRATE?
What are the global sales for ORPHENADRINE CITRATE?
What is Average Wholesale Price for ORPHENADRINE CITRATE?

Summary for ORPHENADRINE CITRATE

US Patents:	0
Applicants:	9
NDAs:	15
Finished Product Suppliers / Packagers:	17
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	1
Patent Applications:	989
Drug Prices:	Drug price information for ORPHENADRINE CITRATE
DailyMed Link:	ORPHENADRINE CITRATE at DailyMed

Drug patent expirations by year for ORPHENADRINE CITRATE

Recent Clinical Trials for ORPHENADRINE CITRATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Baghdad	PHASE4

See all ORPHENADRINE CITRATE clinical trials

Pharmacology for ORPHENADRINE CITRATE

Drug Class	Muscle Relaxant
Physiological Effect	Centrally-mediated Muscle Relaxation

US Patents and Regulatory Information for ORPHENADRINE CITRATE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	ORPHENADRINE CITRATE	orphenadrine citrate	INJECTABLE;INJECTION	040463-001	Mar 4, 2003	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Lupin	ORPHENADRINE CITRATE	orphenadrine citrate	TABLET, EXTENDED RELEASE;ORAL	040284-001	Jun 19, 1998	AB	RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	ORPHENADRINE CITRATE	orphenadrine citrate	INJECTABLE;INJECTION	084779-001	Mar 15, 1982	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Unichem	ORPHENADRINE CITRATE	orphenadrine citrate	TABLET, EXTENDED RELEASE;ORAL	091158-001	Jul 27, 2012	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Rising	ORPHENADRINE CITRATE	orphenadrine citrate	TABLET, EXTENDED RELEASE;ORAL	040249-001	Jan 29, 1999	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Stevens J	ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE	aspirin; caffeine; orphenadrine citrate	TABLET;ORAL	074988-001	Apr 30, 1999		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sandoz	ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE	aspirin; caffeine; orphenadrine citrate	TABLET;ORAL	074654-001	Dec 31, 1996		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.